New Study Reveals Suggestibility’s Role In Antidepressant Effects Of Psilocybin TherapyA new study led by Balázs Szigeti and with involvement of researchers Brandon Weiss, Fernando E Rosas, David Erritzoe, David Nutt and Robin Carhart-Harris found evidence of suggestibility predicting an antidepressant response for patients receiving psilocybin therapy. The study aimed to understand the link between pre-trial expectancy, suggestibility and response to treatment in a previously conducted clinical trial comparing escitalopram and COMPASS Pathways‘ (NASDAQ:CMPS) synthetic psilocybin, COMP360, in …
